GlassScriptPhysician profile
Tyler Selig
NPI 1154999456
$2,277.70
in general payments reported to CMS, 2019-2025
14 companies · $1,306 in 2025
The $1,306 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $232 · 2024: $739 · 2025: $1,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,194 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,193.70 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,047.24 | 2024-2025 | |
| Gilead Sciences, INC. | $519.25 | 2023-2025 | Livdelzi, Epclusa, Vemlidy |
| Janssen Biotech, INC. | $178.10 | 2024-2025 | Tremfya, Stelara |
| Lilly USA, LLC | $143.65 | 2024-2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.70 | 2023-2024 | Xifaxan, Trulance |
| Mallinckrodt Hospital Products INC. | $59.99 | 2024 | Terlivaz |
| Takeda Pharmaceuticals U.S.A., INC. | $39.33 | 2024-2025 | Eohilia |
| Phathom Pharmaceuticals, INC. | $31.92 | 2024 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $27.26 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $21.01 | 2025 | |
| Genzyme Corporation | $18.37 | 2024 | |
| Merck Sharp & Dohme LLC | $17.98 | 2024 | Dificid, Zinplava |
| Ardelyx, INC. | $17.12 | 2023 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $16.78 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Selig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.